Research programme: cancer immunotherapy- PrimeVax Immuno-Oncology

Drug Profile

Research programme: cancer immunotherapy- PrimeVax Immuno-Oncology

Latest Information Update: 09 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Centers for Disease Control and Prevention; PrimeVax Immuno-Oncology
  • Developer PrimeVax Immuno-Oncology
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Feb 2017 PrimeVax Immuno-Oncology intends to file an IND application with the FDA in USA for Cancer
  • 22 Feb 2017 Preclinical trials in Cancer in USA (Parenteral)
  • 22 Feb 2017 PrimeVax Immuno-oncology plans a phase I trial for Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top